EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Evaluation of the tolerance and effects of 1-deoxynojirimycin on insulin and glucose dynamics in healthy horses and horses at risk for insulin dysregulation

Canaan Whitfield-Cargile, Michelle Coleman, Kelsey Hart, Daniel Gomes, Londa Berghaus, Kylee Jo Duberstein, Kenzie Ellis, Amanda Tinkle, Roya Shirzad

Journal of Veterinary Internal Medicine · 02.03.2026 · 40 (2)

DOI: 10.1093/jvimsj/aalag074 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 20.04.2026. Verfasst von Canaan Whitfield-Cargile und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, United States. Hauptthemen laut MEDLINE: 1-Deoxynojirimycin, Insulin, Blood Glucose, Horse Diseases. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Crosswell Chair in Large Animal Medicine, Platinum Performance, LLC, University of Georgia Foundation's Winston and Super Fund for Laminitis and PPID Research, University of Georgia Foundation’s Winston and Super Fund for Laminitis and PPID Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Insulin dysregulation (ID) is common and diminishes welfare of horses. Current management relies on diet and exercise, with variable responses and limited medical options. Alpha-glucosidase inhibitors (AGIs) might provide adjunctive therapy. Hypothesis/Objectives To evaluate the tolerance and effects of Reducose®, a Morus alba leaf extract standardized to 5% 1-deoxynojirimycin (DNJ), in healthy horses and horses at risk of ID. We hypothesized DNJ would be well-tolerated and reduce insulin responses to oral sugar tests (OSTs). Animals Twenty-seven horses: 6 healthy (Phase I), 5 at risk for ID (Phase II), and 16 at risk for ID (Phase III).

Methods

Prospective, 3-phase study. Phase I assessed tolerance of escalating oral DNJ doses (0-5000 mg q12h, 7 days each). Phase II evaluated dose-dependent effects on OST response (0-5000 mg q12h, 7 days each). Phase III assessed duration of effect (0-3 h pre-OST) at 2500 and 5000 mg q12h (28 days each). Primary outcomes were peak insulin and insulin area under the curve (AUC).

Results

DNJ caused no adverse effects. Insulin responses decreased in a dose- and time-dependent manner. At 5000 mg q12h, peak insulin fell from 33.4 ± 15.1 μIU/mL to 18.8 ± 9.2 μIU/mL; AUC decreased by −18.6 μIU·h/mL (95% CI, −31.7 to −5.5). In Phase III, 5000 mg significantly reduced peak insulin when OST was performed 0 h (−13.1 μIU/mL, 95% CI, −18.1 to −8.2) and 1 h (−7.4 μIU/mL, 95% CI, −12.5 to −2.4) after DNJ. Insulin AUC mirrored peak insulin. Conclusions and clinical importance DNJ was well-tolerated and attenuated insulin responses to OST, supporting its potential as adjunctive therapy for ID in horses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

1-DeoxynojirimycinInsulinBlood GlucoseHorse DiseasesGlycoside Hydrolase InhibitorsAnimalsHorsesMaleFemaleGlucose Tolerance TestMorusDose-Response Relationship, DrugProspective StudiesPlant Extracts

Stichwörter der Autor:innen

equine metabolic syndromeglucose regulationinsulin dysregulationΑ-glucosidase inhibitor

Substanzen

1-DeoxynojirimycinInsulinBlood GlucoseGlycoside Hydrolase InhibitorsPlant Extracts

Autor:innen und Institutionen

  • Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, United States.
  • Department of Animal & Dairy Science, College of Agricultural and Environmental Sciences, University of Georgia, Athens, GA 30602, United States.

Förderung

  • Crosswell Chair in Large Animal Medicine, Platinum Performance, LLC
  • University of Georgia Foundation's Winston and Super Fund for Laminitis and PPID Research
  • University of Georgia Foundation’s Winston and Super Fund for Laminitis and PPID Research

Zitieren

APA

Whitfield-Cargile, C., Coleman, M., Hart, K., Gomes, D., Berghaus, L., Duberstein, K. J., Ellis, K., Tinkle, A., & Shirzad, R. (2026). Evaluation of the tolerance and effects of 1-deoxynojirimycin on insulin and glucose dynamics in healthy horses and horses at risk for insulin dysregulation. Journal of Veterinary Internal Medicine, 40(2). https://doi.org/10.1093/jvimsj/aalag074

Vancouver

Whitfield-Cargile C, Coleman M, Hart K, Gomes D, Berghaus L, Duberstein KJ, et al. Evaluation of the tolerance and effects of 1-deoxynojirimycin on insulin and glucose dynamics in healthy horses and horses at risk for insulin dysregulation. Journal of Veterinary Internal Medicine. 2026;40(2). doi:10.1093/jvimsj/aalag074

BibTeX
@article{WhitfieldCargile2026,
  author = {Whitfield-Cargile, Canaan and Coleman, Michelle and Hart, Kelsey and Gomes, Daniel and Berghaus, Londa and Duberstein, Kylee Jo and Ellis, Kenzie and Tinkle, Amanda and Shirzad, Roya},
  title = {Evaluation of the tolerance and effects of 1-deoxynojirimycin on insulin and glucose dynamics in healthy horses and horses at risk for insulin dysregulation},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2026},
  volume = {40},
  number = {2},
  doi = {10.1093/jvimsj/aalag074}
}
Kostenlos starten →